Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inarigivir Soproxil DDI with Midazolam
NCT03493698Phase 1Completed
- Sponsor
- F-star
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inarigivir soproxil in hepatitis B (HBV), sponsored by F-star. Primary endpoints: Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam (Cmax) at Day 19, Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam (AUC0-t) at Day 19 and 1 more. Started May 2018; status: completed.
02
Drugs
inarigivir soproxil
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03493698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493698.